

Russell E. Lewis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3354394/russell-e-lewis-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

282
papers

14,935
citations

71
h-index

112
g-index

291
ext. papers

17,082
ext. citations

7.3
avg, IF

6.66
L-index

#	Paper	IF	Citations
282	Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in <i>Candida</i> spp colonized patients.. <i>International Journal of Infectious Diseases</i> , 2022 ,	10.5	3
281	Investigational antifungal agents for invasive mycoses: a clinical perspective.. <i>Clinical Infectious Diseases</i> , 2022 ,	11.6	6
280	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association.. <i>Lancet Haematology</i> , 2022 , 9, e361-e373	14.6	1
279	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.. <i>Frontiers in Immunology</i> , 2021 , 12, 804988	8.4	0
278	Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. <i>Lancet Haematology</i> , 2021 ,	14.6	6
277	Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3606-e3614	11.6	176
276	Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?. <i>Lancet Haematology</i> , 2021 , 8, e216-e228	14.6	13
275	Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	3
274	Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA). <i>Journal of Infectious Diseases</i> , 2021 ,	7	24
273	Reply to Day et al. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1627-1628	7	1
272	Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions. <i>Current Opinion in Infectious Diseases</i> , 2021 , 34, 288-296	5.4	1
271	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021 , 47, 819-834	14.5	30
270	Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study. <i>Journal of Infection</i> , 2021 , 83, 371-380	18.9	1
269	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020 , 46, 1524-1535	14.5	149
268	How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions. <i>Clinical Infectious Diseases</i> , 2020 , 71, 685-692	11.6	10
267	Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1802-1803	11.6	7
266	Infectious disease consultation for candidaemia. <i>Lancet Infectious Diseases</i> , 2020 , 20, 164	25.5	

265	Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 7,	5.6	17
264	Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Infections in Neutropenic Patients. <i>Microorganisms</i> , 2020 , 8,	4.9	1
263	The timing of plerixafor addition to G-CSF and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020 , 55, 946-954	4.4	3
262	Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3096-3098	5.1	0
261	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020 , 222, S175-S198	7	39
260	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa453	1	5
259	Invasive mould infections in solid organ transplant patients: modifiers and indicators of disease and treatment response. <i>Infection</i> , 2019 , 47, 919-927	5.8	11
258	Live Monitoring and Analysis of Fungal Growth, Viability, and Mycelial Morphology Using the InCuCyte NeuroTrack Processing Module. <i>MBio</i> , 2019 , 10,	7.8	10
257	Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2019 , 68, S244-S259	11.6	26
256	Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2019 , 68, S260-S274	11.6	35
255	Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections. <i>Clinical Infectious Diseases</i> , 2019 , 68, S241-S243	11.6	3
254	Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. <i>Journal of Infection</i> , 2019 , 78, 484-490	18.9	13
253	<i>Saprochaete clavata</i> infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature. <i>Mycoses</i> , 2019 , 62, 1100-1107	5.2	13
252	Beyond biomarkers: How enhanced CT imaging can improve the diagnostic-driven management of invasive mould disease. <i>Medical Mycology</i> , 2019 , 57, S274-S286	3.9	1
251	Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 95, 114861	2.9	5
250	Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing <i>Klebsiella pneumoniae</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 1925-1931	5.3	3
249	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , 2019 , 19, e405-e421	25.5	441
248	Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 ,	5.9	8

247	Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz505	1	15
246	Preexposure to Isavuconazole Increases the Virulence of but Not in a Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	9
245	Extended Infusion of β -Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1731-1739	11.6	14
244	Risk factors for treatment failure in patients receiving β -lactam/ β -lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 574-581	14.3	2
243	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). <i>Annals of Hematology</i> , 2018 , 97, 791-798	3	6
242	Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant <i>Pseudomonas aeruginosa</i> . <i>Microbiology and Immunology</i> , 2018 , 62, 291-294	2.7	6
241	Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or <i>Clostridium difficile</i> infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 516-521	14.3	0
240	The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies. <i>British Journal of Radiology</i> , 2018 , 91, 20170220	3.4	7
239	In vivo evolution of resistant subpopulations of KPC-producing <i>Klebsiella pneumoniae</i> during ceftazidime/avibactam treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1525-1529	5.1	95
238	Successful treatment of bilateral endogenous <i>Fusarium solani</i> endophthalmitis in a patient with acute lymphocytic leukaemia. <i>Mycoses</i> , 2018 , 61, 53-60	5.2	8
237	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infection. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 244-248	14.3	42
236	Potential role of T2Candida in the management of empirical antifungal treatment in patients at high risk of candidaemia: a pilot single-centre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2856-2859	5.1	8
235	Clinical Approach to Infections in the Compromised Host 2018 , 1447-1461		
234	Azole-Resistance in and Related Species: An Emerging Problem or a Rare Phenomenon?. <i>Frontiers in Microbiology</i> , 2018 , 9, 516	5.7	46
233	Overview of antifungal dosing in invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, i33-i43	5.1	26
232	Development and Applications of Prognostic Risk Models in the Management of Invasive Mold Disease. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	5
231	The role of extended infusion β -lactams in the treatment of bloodstream infections in patients with liver cirrhosis. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 771-779	5.5	3
230	Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1621-1630	11.6	59

229	Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment. <i>Transplant Infectious Disease</i> , 2017 , 19, e12658	2.7	7
228	Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	14
227	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015. <i>Clinical Infectious Diseases</i> , 2017 , 65, 216-225	11.6	39
226	In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing <i>Klebsiella pneumoniae</i> clinical isolates. <i>International Journal of Infectious Diseases</i> , 2017 , 65, 1-3	10.5	27
225	Animal Models for Studying Triazole Resistance in <i>Aspergillus fumigatus</i> . <i>Journal of Infectious Diseases</i> , 2017 , 216, S466-S473	7	11
224	Risk factors for recurrent carbapenem resistant <i>Klebsiella pneumoniae</i> bloodstream infection: a prospective cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 1965-1970	5.3	11
223	Radiologic findings of <i>Fusarium pneumonia</i> in neutropenic patients. <i>Mycoses</i> , 2017 , 60, 73-78	5.2	10
222	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017 , 92, 37-41	7.1	53
221	Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of <i>Rhizopus oryzae</i> . <i>Journal of Infectious Diseases</i> , 2016 , 214, 114-21	7	17
220	Improved Radiographic Imaging of Invasive Fungal Disease: The Cornerstone to Antifungal Stewardship in the Hematology Units?. <i>Current Fungal Infection Reports</i> , 2016 , 10, 78-86	1.4	5
219	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 1914-21	12.9	88
218	Bloodstream infections in patients with liver cirrhosis. <i>Virulence</i> , 2016 , 7, 309-19	4.7	48
217	Mucorales-Specific T Cells in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2016 , 11, e0149108	3.7	27
216	Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians. <i>Current Opinion in Pharmacology</i> , 2015 , 24, 30-7	5.1	33
215	Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant <i>Candida glabrata</i> isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5405-12	5.9	9
214	Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis. <i>Annals of Pharmacotherapy</i> , 2015 , 49, 978-85	2.9	7
213	High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies. <i>Clinical Infectious Diseases</i> , 2015 , 60, 1603-10	11.6	65
212	Computerized tomographic pulmonary angiography discriminates invasive mould disease of the lung from lymphoma. <i>British Journal of Haematology</i> , 2015 , 169, 462	4.5	2

211	Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β -Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae. <i>Infectious Diseases and Therapy</i> , 2015 , 4, 65-83	6.2	32
210	Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 242-7	9.5	52
209	High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial. <i>Transplantation</i> , 2015 , 99, 848-54	1.8	20
208	Agents of Mucormycosis and Entomophthoromycosis 2015 , 2909-2919.e3		8
207	Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization. <i>American Journal of Transplantation</i> , 2015 , 15, 1708-15	8.7	77
206	Antifungal Agents 2015 , 79-97		1
205	Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7830-2	5.9	8
204	Serum galactomannan diagnosis of breakthrough invasive fungal disease. <i>Clinical Infectious Diseases</i> , 2015 , 60, 1284	11.6	2
203	Treatment principles for the management of mold infections. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014 , 5,	5.4	14
202	Different recommendations for daptomycin dosing over time in patients with severe infections. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1788-9	11.6	11
201	Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1738-43	5.9	12
200	In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1856-65	5.1	58
199	Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1972-6	5.9	51
198	Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. <i>Mycoses</i> , 2014 , 57, 49-55	5.2	21
197	Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation: a management challenge. <i>Liver Transplantation</i> , 2014 , 20, 631-3	4.5	6
196	Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. <i>Journal of Hepatology</i> , 2014 , 61, 51-8	13.4	82
195	Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2775-80	5.9	32
194	Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 865-73	5.9	37

193	Reply to "Risk for invasive fungal infections during acute myeloid leukemia induction therapy: a true association with echinocandins?". <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4990-1	5.9	
192	Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. <i>Medicine (United States)</i> , 2014 , 93, 298-309	1.8	75
191	Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible <i>Candida parapsilosis</i> isolates with different degrees of caspofungin susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 229-36	5.9	10
190	Risk factors for carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infection among rectal carriers: a prospective observational multicentre study. <i>Clinical Microbiology and Infection</i> , 2014 , 20, 1357-62	9.5	133
189	Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 6767-72	5.9	37
188	Immunomodulatory Agents as Adjunctive Therapy for the Treatment of Resistant <i>Candida</i> Species. <i>Current Fungal Infection Reports</i> , 2013 , 7, 119-125	1.4	2
187	Routine use of a real-time polymerase chain reaction method for detection of bloodstream infections in neutropaenic patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013 , 75, 130-4	2.9	33
186	Epidemiology and treatment of mucormycosis. <i>Future Microbiology</i> , 2013 , 8, 1163-75	2.9	64
185	Predictors of mortality in multidrug-resistant <i>Klebsiella pneumoniae</i> bloodstream infections. <i>Expert Review of Anti-Infective Therapy</i> , 2013 , 11, 1053-63	5.5	65
184	Aggressive versus conservative initiation of antibiotics. <i>Lancet Infectious Diseases</i> , 2013 , 13, 387	25.5	2
183	Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1730-3	1.9	25
182	Treatment of carbapenem-resistant <i>Klebsiella pneumoniae</i> : the state of the art. <i>Expert Review of Anti-Infective Therapy</i> , 2013 , 11, 159-77	5.5	104
181	<i>Drosophila melanogaster</i> as a model to explore the effects of methicillin-resistant <i>Staphylococcus aureus</i> strain type on virulence and response to linezolid treatment. <i>Microbial Pathogenesis</i> , 2013 , 55, 16-20	3.8	7
180	The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis. <i>Bone Marrow Transplantation</i> , 2013 , 48, 141-3	4.4	14
179	Tacrolimus enhances the potency of posaconazole against <i>Rhizopus oryzae</i> in vitro and in an experimental model of mucormycosis. <i>Journal of Infectious Diseases</i> , 2013 , 207, 834-41	7	43
178	Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. <i>Journal of Infectious Diseases</i> , 2013 , 207, 1066-74	7	18
177	Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 3990-3	5.9	87
176	High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental <i>Aspergillus terreus</i> pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1148-51	5.1	9

175	Hyperthermia sensitizes <i>Rhizopus oryzae</i> to posaconazole and itraconazole action through apoptosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 4360-8	5.9	15
174	Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. <i>Mycoses</i> , 2013 , 56, 638-45	5.2	160
173	A risk prediction score for invasive mold disease in patients with hematological malignancies. <i>PLoS ONE</i> , 2013 , 8, e75531	3.7	45
172	Rare opportunistic (non- <i>Candida</i> , non- <i>Cryptococcus</i>) yeast bloodstream infections in patients with cancer. <i>Journal of Infection</i> , 2012 , 64, 68-75	18.9	104
171	Echinocandin resistance in <i>Candida</i> species: mechanisms of reduced susceptibility and therapeutic approaches. <i>Annals of Pharmacotherapy</i> , 2012 , 46, 1086-96	2.9	77
170	Interactions of liposome carriers with infectious fungal hyphae reveals the role of β -glucans. <i>Molecular Pharmaceutics</i> , 2012 , 9, 2489-96	5.6	7
169	Update on Amphotericin B Pharmacology and Dosing for Common Systemic Mycoses. <i>Current Fungal Infection Reports</i> , 2012 , 6, 349-357	1.4	2
168	How does antifungal pharmacology differ for mucormycosis versus aspergillosis?. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 1, S67-72	11.6	45
167	Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections. <i>American Journal of Therapeutics</i> , 2012 , 19, 51-63	1	7
166	Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. <i>Clinical Infectious Diseases</i> , 2012 , 54, 610-6	11.6	48
165	Combination therapy for mucormycosis: why, what, and how?. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 1, S73-8	11.6	111
164	Future directions in mucormycosis research. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 1, S79-85	11.6	34
163	Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 422-9	5.1	4
162	Mouse models for the study of fungal pneumonia: a collection of detailed experimental protocols for the study of <i>Coccidioides</i> , <i>Cryptococcus</i> , <i>Fusarium</i> , <i>Histoplasma</i> and combined infection due to <i>Aspergillus-Rhizopus</i> . <i>Virulence</i> , 2012 , 3, 329-38	4.7	11
161	The potential impact of antifungal drug resistance mechanisms on the host immune response to <i>Candida</i> . <i>Virulence</i> , 2012 , 3, 368-76	4.7	31
160	Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies. <i>Medical Mycology</i> , 2012 , 50, 543-8	3.9	16
159	Invasive Mold Infections in Pediatric Cancer Patients Reflect Heterogeneity in Etiology, Presentation, and Outcome: A 10-Year, Single-Institution, Retrospective Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2012 , 1, 125-35	4.8	19
158	Current concepts in antifungal pharmacology. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 805-17	6.4	248

157	Pharmacokinetic-pharmacodynamic optimization of triazole antifungal therapy. <i>Current Opinion in Infectious Diseases</i> , 2011 , 24, S14-S29	5.4	9
156	How I treat mucormycosis. <i>Blood</i> , 2011 , 118, 1216-24	2.2	224
155	In vitro interactions among echinocandins against <i>Aspergillus fumigatus</i> : lack of concordance among methods. <i>Medical Mycology</i> , 2011 , 49, 285-8	3.9	7
154	Cutaneous Mucormycosis in Tornado Survivors. <i>Current Fungal Infection Reports</i> , 2011 , 5, 187-189	1.4	2
153	Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of <i>Aspergillus fumigatus</i> - <i>Rhizopus oryzae</i> pulmonary infection. <i>Virulence</i> , 2011 , 2, 348-55	4.7	40
152	Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3584-7	5.9	9
151	Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of <i>Candida</i> and <i>Aspergillus</i> species. <i>Virulence</i> , 2011 , 2, 280-95	4.7	24
150	Mucormycosis caused by unusual mucormycetes, non- <i>Rhizopus</i> , - <i>Mucor</i> , and - <i>Lichtheimia</i> species. <i>Clinical Microbiology Reviews</i> , 2011 , 24, 411-45	34	251
149	Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant <i>Aspergillus fumigatus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1324-31	5.1	15
148	Activity of deferasirox in Mucorales: influences of species and exogenous iron. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 411-3	5.9	21
147	Fitness and virulence costs of <i>Candida albicans</i> FKS1 hot spot mutations associated with echinocandin resistance. <i>Journal of Infectious Diseases</i> , 2011 , 204, 626-35	7	106
146	Fungal Drug Resistance and Pharmacologic Considerations of Dosing Newer Antifungal Therapies 2011 , 317-329		
145	Enemy of the (immunosuppressed) state: an update on the pathogenesis of <i>Aspergillus fumigatus</i> infection. <i>British Journal of Haematology</i> , 2010 , 150, 406-17	4.5	83
144	Caspofungin-non-susceptible <i>Candida</i> isolates in cancer patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 293-5	5.1	34
143	Antifungal activity of colistin against mucorales species in vitro and in a murine model of <i>Rhizopus oryzae</i> pulmonary infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 484-90	5.9	44
142	Interstrain variability in the virulence of <i>Aspergillus fumigatus</i> and <i>Aspergillus terreus</i> in a Toll-deficient <i>Drosophila</i> fly model of invasive aspergillosis. <i>Medical Mycology</i> , 2010 , 48, 310-317	3.9	24
141	Cutaneous model of invasive aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1848-54	5.9	29
140	Exploring the concordance of <i>Aspergillus fumigatus</i> pathogenicity in mice and Toll-deficient flies. <i>Medical Mycology</i> , 2010 , 48, 506-10	3.9	24

139	Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1298-304	5.9	57
138	Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis. <i>Medical Mycology</i> , 2010 , 48, 817-23	3.9	30
137	Toll-deficient <i>Drosophila</i> are resistant to infection by <i>Pneumocystis</i> spp.: additional evidence of specificity to mammalian hosts. <i>Virulence</i> , 2010 , 1, 523-5	4.7	4
136	Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2010 , 42, 40-50	5.7	81
135	Characterization of a 5-azacytidine-induced developmental <i>Aspergillus fumigatus</i> variant. <i>Virulence</i> , 2010 , 1, 164-73	4.7	15
134	Lack of galactomannan reactivity in dematiaceous molds recovered from cancer patients with phaeohyphomycosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010 , 66, 200-3	2.9	9
133	Fungal infections in leukemia patients: how do we prevent and treat them?. <i>Clinical Infectious Diseases</i> , 2010 , 50, 405-15	11.6	109
132	Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. <i>Journal of Infection</i> , 2010 , 60, 331-7	18.9	118
131	Antifungal Therapeutic Drug Monitoring. <i>Current Fungal Infection Reports</i> , 2010 , 4, 158-167	1.4	20
130	Agents of Mucormycosis and Entomophthoromycosis 2010 , 3257-3269		8
129	Interstrain variability in the virulence of <i>Aspergillus fumigatus</i> and <i>Aspergillus terreus</i> in a Toll-deficient <i>Drosophila</i> fly model of invasive aspergillosis. <i>Medical Mycology</i> , 2010 , 48, 310-7	3.9	15
128	Antifungal activity against <i>Scedosporium</i> species and novel assays to assess antifungal pharmacodynamics against filamentous fungi. <i>Medical Mycology</i> , 2009 , 47, 422-32	3.9	29
127	Invasive aspergillosis in glucocorticoid-treated patients. <i>Medical Mycology</i> , 2009 , 47 Suppl 1, S271-81	3.9	75
126	Phaeohyphomycosis in a tertiary care cancer center. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1033-41	11.6	104
125	<i>Candida albicans</i> Cas5, a regulator of cell wall integrity, is required for virulence in murine and toll mutant fly models. <i>Journal of Infectious Diseases</i> , 2009 , 200, 152-7	7	41
124	Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. <i>Journal of Infectious Diseases</i> , 2009 , 199, 1399-406	7	104
123	Culture medium composition affects the lethality of <i>Cunninghamella bertholletiae</i> in a fly model of mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 4569	5.9	8
122	Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. <i>Cancer</i> , 2009 , 115, 4745-52	6.4	206

121	Immunomodulating effects of antifungal therapy. <i>Current Fungal Infection Reports</i> , 2009 , 3, 243-250	1.4	3
120	Azoles and antidepressants: a mini-review of the tolerability of co-administration. <i>Mycoses</i> , 2009 , 52, 433-9	5.2	1
119	Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?. <i>Clinical Microbiology and Infection</i> , 2009 , 15 Suppl 5, 93-7	9.5	78
118	A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. <i>Journal of Infection</i> , 2009 , 59, 134-8	18.9	58
117	Increased bacterial adherence and biomass in <i>Pseudomonas aeruginosa</i> bacteria exposed to clarithromycin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 63, 81-6	2.9	13
116	In vivo dynamics of carbapenem-resistant <i>Pseudomonas aeruginosa</i> selection after suboptimal dosing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 64, 427-33	2.9	16
115	The burden of bacterial and viral infections in hematopoietic stem cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 128-33	4.7	17
114	Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study. <i>International Journal of Antimicrobial Agents</i> , 2009 , 34, 95-8	14.3	13
113	Overview of the changing epidemiology of candidemia. <i>Current Medical Research and Opinion</i> , 2009 , 25, 1732-40	2.5	64
112	<i>Aspergillus fumigatus</i> inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. <i>Blood</i> , 2009 , 114, 5393-9	2.2	81
111	Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. <i>Current Opinion in Infectious Diseases</i> , 2009 , 22, 376-84	5.4	28
110	Polyene Antifungal Agents 2009 , 281-305		
109	<i>Candida lusitanae</i> fungemia in cancer patients: risk factors for amphotericin B failure and outcome. <i>Medical Mycology</i> , 2008 , 46, 541-6	3.9	70
108	What is the "therapeutic range" for voriconazole?. <i>Clinical Infectious Diseases</i> , 2008 , 46, 212-4	11.6	43
107	Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 4178-80	5.9	20
106	Immunocompromised hosts: immunopharmacology of modern antifungals. <i>Clinical Infectious Diseases</i> , 2008 , 47, 226-35	11.6	109
105	Does pre-exposure of <i>Aspergillus fumigatus</i> to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 539-42	5.1	12
104	<i>Zygomycetes</i> hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 722-4	5.9	65

103	Caspofungin-resistant <i>Candida tropicalis</i> strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 4181-3	5.9	113
102	Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. <i>Clinical Infectious Diseases</i> , 2008 , 47, 503-9	11.6	489
101	Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 1140-4	5.1	54
100	Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against <i>Aspergillus</i> and non- <i>Aspergillus</i> hyphae. <i>Journal of Infectious Diseases</i> , 2008 , 198, 186-92	7	156
99	Genomewide screening for genes associated with gliotoxin resistance and sensitivity in <i>Saccharomyces cerevisiae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1325-9	5.9	8
98	Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against <i>Cryptococcus neoformans</i> isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 735-8	5.9	77
97	<i>Drosophila melanogaster</i> as a model host to dissect the immunopathogenesis of zygomycosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 9367-72	11.5	106
96	Pharmacokinetic considerations for the use of newer antifungal agents. <i>Current Fungal Infection Reports</i> , 2008 , 2, 5-11	1.4	
95	Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2008 , 27, 343-7	5.3	49
94	Antifungal Agents 2008 , 105-133		
93	Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. <i>Cancer</i> , 2007 , 110, 1303-6	6.4	127
92	Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. <i>Pharmacotherapy</i> , 2007 , 27, 1644-50	5.8	63
91	Random plasma concentrations of voriconazole decline over time. <i>Journal of Infection</i> , 2007 , 55, e129-30	8.9	26
90	Paradoxical effect of Echinocandins across <i>Candida</i> species in vitro: evidence for echinocandin-specific and candida species-related differences. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 2257-9	5.9	146
89	Effects of <i>Aspergillus fumigatus</i> gliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis. <i>Journal of Leukocyte Biology</i> , 2007 , 82, 839-48	6.5	47
88	Posaconazole prophylaxis in hematologic cancer. <i>New England Journal of Medicine</i> , 2007 , 356, 2214; author reply 2215-8	59.2	9
87	Increased culture recovery of Zygomycetes under physiologic temperature conditions. <i>American Journal of Clinical Pathology</i> , 2007 , 127, 208-12	1.9	39
86	Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1078-81	5.9	37

85	Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1253-8	5.9	60
84	Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: A hypothesis. <i>Fungal Genetics and Biology</i> , 2007 , 44, 88-92	3.9	10
83	Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. <i>Clinical Therapeutics</i> , 2007 , 29, 1980-6	3.5	27
82	Pharmacodynamic implications for use of antifungal agents. <i>Current Opinion in Pharmacology</i> , 2007 , 7, 491-7	5.1	30
81	Role of mini-host models in the study of medically important fungi. <i>Lancet Infectious Diseases</i> , 2007 , 7, 42-55	25.5	70
80	Virulence studies of <i>Scedosporium</i> and <i>Fusarium</i> species in <i>Drosophila melanogaster</i> . <i>Journal of Infectious Diseases</i> , 2007 , 196, 1860-4	7	30
79	Posaconazole prophylaxis in hematologic cancer. <i>New England Journal of Medicine</i> , 2007 , 356, 2214-5; author reply 2215-8	59.2	2
78	Decision making in antifungal monotherapy versus combination therapy. <i>Pharmacotherapy</i> , 2006 , 26, 61S-67S	5.8	9
77	Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 294-7	5.9	8
76	In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against <i>Candida</i> species in the presence of human serum albumin. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 288-93	5.1	18
75	Managing drug interactions in the patient with aspergillosis. <i>Medical Mycology</i> , 2006 , 44, S349-S356	3.9	44
74	Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 469-73	5.9	84
73	Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. <i>Transplantation</i> , 2006 , 81, 320-6	1.8	250
72	<i>Scedosporium</i> infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. <i>Clinical Infectious Diseases</i> , 2006 , 43, 1580-4	11.6	133
71	Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox ^{-/-} mouse model of chronic granulomatous disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 422-7	5.9	58
70	Inhibition of <i>Candida parapsilosis</i> mitochondrial respiratory pathways enhances susceptibility to caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 744-7	5.9	32
69	Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. <i>Infectious Disease Clinics of North America</i> , 2006 , 20, 581-607, vi	6.5	185
68	<i>Drosophila melanogaster</i> as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in <i>Candida</i> species. <i>Journal of Infectious Diseases</i> , 2006 , 193, 1014-22	7	91

67	Pharmacology of Systemic Antifungal Agents. <i>Clinical Infectious Diseases</i> , 2006 , 43, S28-S39	11.6	211
66	Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 96-103	5.9	92
65	Judgments of Value, Judgments of Fact: The Ethical Dimension of Biohistorical Research. <i>Public Historian</i> , 2006 , 28, 93-99	0.2	2
64	Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. <i>Mycoses</i> , 2006 , 49, 226-31	5.2	28
63	Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). <i>Haematologica</i> , 2006 , 91, 986-9	6.6	333
62	Pharmacodynamics of polymyxin B against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 3624-30	5.9	168
61	Increased frequency of non-fumigatus <i>Aspergillus</i> species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005 , 52, 15-20	2.9	75
60	Murine model of invasive aspergillosis. <i>Methods in Molecular Medicine</i> , 2005 , 118, 129-42		21
59	<i>Aspergillus fumigatus</i> suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. <i>Blood</i> , 2005 , 105, 2258-65	2.2	152
58	<i>Aspergillus</i> susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. <i>Pharmacotherapy</i> , 2005 , 25, 1174-80	5.8	32
57	Toll-deficient <i>Drosophila</i> flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and <i>Aspergillus</i> virulence. <i>Journal of Infectious Diseases</i> , 2005 , 191, 1188-95	7	73
56	Micafungin in combination with voriconazole in <i>Aspergillus</i> species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 56, 887-92	5.1	30
55	Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 792-5	5.1	44
54	Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. <i>Clinical Infectious Diseases</i> , 2005 , 41, 60-6	11.6	269
53	Attenuation of the activity of caspofungin at high concentrations against <i>Candida albicans</i> : possible role of cell wall integrity and calcineurin pathways. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 5146-8	5.9	113
52	Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis. <i>Infection and Immunity</i> , 2005 , 73, 7747-58	3.7	10
51	Caspofungin versus liposomal amphotericin B for empirical therapy. <i>New England Journal of Medicine</i> , 2005 , 352, 410-4; author reply 410-4	59.2	12
50	Frequency and species distribution of gliotoxin-producing <i>Aspergillus</i> isolates recovered from patients at a tertiary-care cancer center. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 6120-2	9.7	88

49	Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. <i>Journal of Infectious Diseases</i> , 2005 , 191, 1350-60	7	583
48	In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 945-51	5.9	99
47	Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 5046-50	5.9	50
46	Detection of gliotoxin in experimental and human aspergillosis. <i>Infection and Immunity</i> , 2005 , 73, 635-7	3.7	144
45	Ethics. Constructing ethical guidelines for biohistory. <i>Science</i> , 2004 , 304, 215-6	33.3	12
44	Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4315-21	5.9	33
43	Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 54, 376-85	5.1	90
42	Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. <i>Journal of Infectious Diseases</i> , 2004 , 190, 1464-71	7	185
41	Challenges in designing animal studies to detect antagonism of polyene activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 3211; author reply 3211-2	5.9	1
40	Challenges in Designing Animal Studies To Detect Antagonism of Polyene Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4072-4072	5.9	78
39	Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 2490-6	5.9	48
38	Toward more effective antifungal therapy: the prospects of combination therapy. <i>British Journal of Haematology</i> , 2004 , 126, 165-75	4.5	69
37	Screening of Antibacterial and Antifungal Activities of Ten Medicinal Plants from Ghana. <i>Pharmaceutical Biology</i> , 2004 , 42, 13-17	3.8	19
36	The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 1313-33	5.9	119
35	Attenuation of itraconazole fungicidal activity following preexposure of Aspergillus fumigatus to fluconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 3592-7	5.9	18
34	Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. <i>Medicine (United States)</i> , 2003 , 82, 309-21	1.8	101
33	Invasive aspergillosis in patients with hematologic malignancies. <i>Pharmacotherapy</i> , 2003 , 23, 1592-610	5.8	41
32	Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. <i>Cancer</i> , 2003 , 98, 292-9	6.4	244

31	Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. <i>Drug Resistance Updates</i> , 2003 , 6, 257-69	23.2	48
30	Aspergillosis caused by non-fumigatus <i>Aspergillus</i> species: risk factors and in vitro susceptibility compared with <i>Aspergillus fumigatus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2003 , 46, 25-8	2.9	48
29	Sequential exposure of <i>Aspergillus fumigatus</i> to itraconazole and caspofungin: evidence of enhanced in vitro activity. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003 , 47, 415-9	2.9	18
28	The activity of amphotericin B against <i>Candida albicans</i> is not directly associated with extracellular calcium concentration. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 305-12	5.1	3
27	Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in <i>Aspergillus</i> species. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 313-6	5.1	95
26	The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?. <i>Clinical Infectious Diseases</i> , 2003 , 37, 871-2	11.6	42
25	Pentamidine is active in vitro against <i>Fusarium</i> species. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 3252-9	5.9	21
24	<i>Aspergillus nidulans</i> is frequently resistant to amphotericin B. <i>Mycoses</i> , 2002 , 45, 406-7	5.2	64
23	Pharmacotherapy of <i>Candida</i> bloodstream infections: new treatment options, new era. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 1039-57	4	6
22	Lack of catheter infection by the <i>efg1/efg1 cph1/cph1</i> double-null mutant, a <i>Candida albicans</i> strain that is defective in filamentous growth. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 1153-5	5.9	55
21	Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of <i>Candida</i> catheter-related bloodstream infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 3499-505	5.9	84
20	Pulmonary candidiasis in patients with cancer: an autopsy study. <i>Clinical Infectious Diseases</i> , 2002 , 34, 400-3	11.6	81
19	Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 3208-14	5.9	79
18	Antifungal drug resistance of pathogenic fungi. <i>Lancet, The</i> , 2002 , 359, 1135-44	40	332
17	Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against <i>Candida</i> spp. and <i>Cryptococcus neoformans</i> via time-kill methods. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002 , 43, 13-7	2.9	82
16	Rationale for combination antifungal therapy. <i>Pharmacotherapy</i> , 2001 , 21, 149S-164S	5.8	80
15	Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. <i>Clinical Infectious Diseases</i> , 2001 , 32, E94-6	11.6	13
14	<i>Candida lusitanae</i> catheter-related sepsis. <i>Annals of Pharmacotherapy</i> , 2001 , 35, 1570-4	2.9	12

13	Evaluation of amphotericin B and flucytosine in combination against <i>Candida albicans</i> and <i>Cryptococcus neoformans</i> using time-kill methodology. <i>Diagnostic Microbiology and Infectious Disease</i> , 2001 , 41, 121-6	2.9	30
12	Evaluation of voriconazole pharmacodynamics using time-kill methodology. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1917-20	5.9	92
11	Itraconazole-amphotericin B antagonism in <i>Aspergillus fumigatus</i> : an E-test-based strategy. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 2915-8	5.9	68
10	Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against <i>Bacteroides</i> spp. using an in vitro model of infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2000 , 37, 51-5	2.9	10
9	In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. <i>Diagnostic Microbiology and Infectious Disease</i> , 2000 , 36, 101-5	2.9	30
8	Evaluation of low-dose, extended-interval clindamycin regimens against <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> using a dynamic in vitro model of infection. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 2005-9	5.9	17
7	The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. <i>American Journal of Health-System Pharmacy</i> , 1999 , 56, 525-533	2.2	27
6	Therapy of <i>Candida</i> infections: susceptibility testing, resistance, and therapeutic options. <i>Annals of Pharmacotherapy</i> , 1998 , 32, 1353-61	2.9	18
5	Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 1207-12	5.9	205
4	Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against <i>Candida albicans</i> by using a dynamic in vitro mycotic infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 1382-6	5.9	81
3	Combination Systemic Antifungal Therapy for Cryptococcosis, Candidiasis, and Aspergillosis. <i>Journal of Public Health Pharmacy</i> , 1998 , 3, 61-84		17
2	The Impact of Antifungal Drug Resistance in the Clinic		373-385 1
1	Antifungal Drug Interactions		445-456 1